Decitabine represses translocated MYC oncogene in Burkitt lymphoma

Journal of Pathology

Volumn 229, Issue 5, 2013, Pages 775-783

  Guan, Hanfeng ^a,b   Xie, Linka ^b,c   Klapproth, Kay ^d   Weitzer, Clarissa D ^b   Wirth, Thomas ^b   Ushmorov, Alexey ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF ULM   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Burkitt lymphoma; decitabine; ID2; MYC

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN M; INHIBITOR OF DIFFERENTIATION 2; RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE LOCUS; GENE REPRESSION; ONCOGENE MYC; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENETIC REPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN M; INHIBITOR OF DIFFERENTIATION PROTEIN 2; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSLOCATION, GENETIC; UP-REGULATION;

EID: 84875054244     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4164     Document Type: Article

References (36)

1. Blum KA, Lozanski G, Byrd JC,. Adult Burkitt leukemia and lymphoma. Blood 2004; 104: 3009-3020.
2. Adams JM, Harris AW, Pinkert CA, et al,. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
3. Martin-Subero JI, Kreuz M, Bibikova M, et al,. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009; 113: 2488-2497.
4. Guan H, Xie L, Leithauser F, et al,. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 2010; 116: 1469-1478.
5. Lindstrom MS, Wiman KG,. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 2002; 12: 381-387.
6. Garrison SP, Jeffers JR, Yang C, et al,. Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 2008; 28: 5391-5402.
7. Richter-Larrea JA, Robles EF, Fresquet V, et al,. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531-2542.
8. Taby R, Issa JP,. Cancer epigenetics. CA Cancer J Clin 2010; 60: 376-392.
9. Issa JP, Garcia-Manero G, Giles FJ, et al,. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-1640.
10. Ehlers A, Oker E, Bentink S, et al,. Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype. Leukemia 2008; 22: 835-841.
11. Cutrona G, Carpaneto EM, Ponzanelli A, et al,. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the Eμ enhancer. Cancer Res 2003; 63: 6144-6148.
12. Baghdoyan S, Lamartine J, Castel D, et al,. Id2 reverses cell cycle arrest induced by γ-irradiation in human HaCaT keratinocytes. J Biol Chem 2005; 280: 15836-15841.
13. Bornkamm GW, Berens C, Kuklik-Roos C, et al,. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res 2005; 33: e137.
14. Klapproth K, Sander S, Marinkovic D, et al,. The IKK2/NF-κB pathway suppresses MYC-induced lymphomagenesis. Blood 2009; 114: 2448-2458.
15. Maier HJ, Marienfeld R, Wirth T, et al,. Critical role of RelB serine 368 for dimerization and p100 stabilization. J Biol Chem 2003; 278: 39242-39250.
16. Theil J, Laumen H, Marafioti T, et al,. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 2001; 97: 3191-3196.
17. Atallah E, Kantarjian H, Garcia-Manero G,. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2007; 8: 65-73.
18. Bender CM, Gonzalgo ML, Gonzales FA, et al,. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999; 19: 6690-6698.
19. Ushmorov A, Leithauser F, Sakk O, et al,. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107: 2493-2500.
20. Ushmorov A, Leithauser F, Ritz O, et al,. ABF-1 is frequently silenced by promoter methylation in follicular lymphoma, diffuse large B-cell lymphoma and Burkitt's lymphoma. Leukemia 2008; 22: 1942-1944.
21. Dyer MJ, Fischer P, Nacheva E, et al,. A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t(14;18) and t(4;11) chromosomal translocations. Blood 1990; 75: 709-714.
22. Lam LT, Davis RE, Pierce J, et al,. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28-40.
23. Hoglund A, Nilsson LM, Forshell LP, et al,. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113: 4281-4288.
24. Appleton K, Mackay HJ, Judson I, et al,. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25: 4603-4609.
25. Lasorella A, Noseda M, Beyna M, et al,. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000; 407: 592-598.
26. Cotta CV, Leventaki V, Atsaves V, et al,. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. Cancer 2008; 112: 552-561.
27. Rockman SP, Currie SA, Ciavarella M, et al,. Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem 2001; 276: 45113-45119.
28. Lasorella A, Boldrini R, Dominici C, et al,. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002; 62: 301-306.
29. Nishimori H, Sasaki Y, Yoshida K, et al,. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene 2002; 21: 8302-8309.
30. Spender LC, Inman GJ,. TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1. J Biol Chem 2009; 284: 1435-1442.
31. Nilsson JA, Nilsson LM, Keller U, et al,. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res 2004; 64: 7296-7301.
32. Dave SS, Fu K, Wright GW, et al,. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
33. Kim NS, Kim HJ, Koo BK, et al,. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006; 26: 1002-1013.
34. Vockerodt M, Morgan SL, Kuo M, et al,. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol 2008; 216: 83-92.
35. Panta GR, Kaur S, Cavin LG, et al,. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 2004; 24: 1823-1835.
36. Barrans S, Crouch S, Smith A, et al,. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-3365.